1
|
Takeda A, Baba T, Watanabe J, Nakayama M, Hozawa H, Ishido M. Levodopa Prescription Patterns in Patients with Advanced Parkinson's Disease: A Japanese Database Analysis. Parkinsons Dis 2023; 2023:9404207. [PMID: 37799489 PMCID: PMC10550461 DOI: 10.1155/2023/9404207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 08/04/2023] [Accepted: 08/11/2023] [Indexed: 10/07/2023]
Abstract
Prescription doses of levodopa in patients with advanced Parkinson's disease (PD) are generally lower in Japan than in the United States or Europe, although Japanese guidelines for the management of PD recommend increasing the dosage as the disease progresses. However, data regarding levodopa prescription practices in patients with advanced PD in the clinical setting are limited. This retrospective observational study analyzed patterns of drug use for patients with advanced PD in Japan using claims data from hospitalized patients in the Medical Data Vision Co. database. Eligible patients had at least two PD-associated claims in two different quarters between April 1, 2008, and November 30, 2018, and a 10-item activities of daily living score <60 upon hospital discharge (as a proxy for advanced PD). The primary endpoint was the prescribed dosage of levodopa at the index hospitalization. Dosages of other PD drugs (medications with an on-label indication for PD) and non-PD drugs were also assessed. Overall, 4029 patients met the inclusion criteria (mean age, 76.9 years; 83.3% aged ≥70 years). At the index date, 74.0% were receiving levodopa. Patients received a median of one PD drug in addition to levodopa, and 27.4% and 20.2% received one or two concomitant PD drugs, respectively. Patients received a median of two non-PD drugs. The median levodopa dosage and total levodopa equivalent dosage (LED) at the index hospitalization were 418.2 and 634.8 mg/day (adjusted for body weight, 9.0 and 13.7 mg/kg/day), respectively. The median levodopa and total LED dosage in each 6-month increment during the 5 years before and after the index date ranged between 263.9 and 330.2 mg/day (5.0 and 6.5 mg/kg/day) and 402.0 and 504.9 mg/day (8.3 and 10.1 mg/kg/day), respectively. This study suggests that many Japanese patients with advanced PD could receive more intensive treatment with higher doses of levodopa.
Collapse
Affiliation(s)
- Atsushi Takeda
- Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, 2-11-11 Kagitorihoncho, Taihaku-ku, Sendai 982-8555, Japan
- Department of Cognitive & Motor Aging, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aobaku, Sendai 980-8575, Japan
| | - Toru Baba
- Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, 2-11-11 Kagitorihoncho, Taihaku-ku, Sendai 982-8555, Japan
| | - Jun Watanabe
- Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
| | - Masahiko Nakayama
- Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
| | - Hiroyuki Hozawa
- Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
| | - Miwako Ishido
- Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo 108-0023, Japan
| |
Collapse
|
2
|
KATO R, Suzuki Y, Suzuki H, Aoki R, Koizumi A, Lee M, Homma N, Fukao Y, Nakayama M, Nihei Y, Muto M, Kano T, Makita Y, Miyazaki T, Arai S. WCN23-0498 The pathogenesis of glomerular inflammatory mechanism through Apoptosis Inhibitor of Macrophage. Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
3
|
LEE M, Suzuki H, Kato R, Fukao Y, Nakayama M, Kano T, Makita Y, Suzuki Y. WCN23-0093 TLR9/TLR7 ARE STRONG CANDIDATES FOR DISEASE-SPECIFIC THERAPEUTIC TARGETS IN IgA NEPHROPATHY. Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
4
|
Otsuka Y, Ishii M, Nakamura T, Tsujita K, Fujita H, Matoba T, Kohro T, Kabutoya T, Kario K, Kiyosue A, Mizuno Y, Nakayama M, Miyamoto Y, Sato H, Nagai R. Impact of BNP level in patients with heart failure on major bleeding events after percutaneous coronary intervention. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aims
The Academic Research Consortium for High Bleeding Risk (ARC-HBR) presents a bleeding risk assessment in antithrombotic therapy for patients post percutaneous coronary intervention (PCI). In Japanese patients, heart failure (HF), peripheral vascular disease, and frailty are established as bleeding risk factors in addition to ARC-HBR. However, it is unknown whether left ventricular function or severity of HF is associated with HBR. The aim of this study was to investigate the association between the severity of HF measured by BNP and future bleeding events after PCI.
Methods
Clinical Deep Data Accumulation System (CLIDAS), a multicenter database with 7 tertiary medical hospitals in JAPAN, was developed to collect data directly for patient characteristics, medications, laboratory test, physiological test, cardiac catheterization and PCI treatment in electronic medical records using Standardized Structured Medical Information eXchange Extended Storage (SS-MIX). This retrospective analysis using CLIDAS database included 7160 patients who underwent PCI during April 2014 and March 2020 in the participating hospitals and also who have completed 3-year follow-up were divided into two groups: No HF (n=6645) and HF (n=515). HF patients were furthermore divided based on high BNP (≥100 pg/ml) group (n=384) and low BNP (<100 pg/ml) group (n=131). Primary outcome was defined as bleeding events according to the moderate and severe bleeding in the GUSTO classification. In addition, secondary endpoint was major adverse cardiovascular events (MACE) defined as a composite of cardiac death, myocardial infraction and stroke.
Results
Multivariable Cox regression adjusted for age, sex, BMI, acute coronary syndrome, hypertension, diabetes, dyslipidemia, chronic kidney disease, hemodialysis, previous PCI, previous coronary artery bypass grafting, prior myocardial infraction, prior stroke, prior atrial fibrillation, prior PVD, left main trunk disease, multivessel disease, and anticoagulants use showed that HF with high BNP was significantly associated with bleeding events (hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.10–2.50), MACE (HR, 2.16; 95% CI, 1.60–2.90), and all-cause death (HR, 1.74; 95% CI, 1.30–2.33), but not HF with low BNP.
Conclusions
The CLIDAS real-world database revealed that HF with high BNP was associated with future bleeding events, suggesting that bleeding risk might be altered depending on severity of HF.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- Y Otsuka
- Kumamoto University Hospital , Kumamoto , Japan
| | - M Ishii
- Kumamoto University Hospital , Kumamoto , Japan
| | - T Nakamura
- Kumamoto University Hospital , Kumamoto , Japan
| | - K Tsujita
- Kumamoto University Hospital , Kumamoto , Japan
| | - H Fujita
- Jichi Medical University , Tochigi , Japan
| | - T Matoba
- Kyushu University , Fukuoka , Japan
| | - T Kohro
- Jichi Medical University , Tochigi , Japan
| | - T Kabutoya
- Jichi Medical University , Tochigi , Japan
| | - K Kario
- Jichi Medical University , Tochigi , Japan
| | | | - Y Mizuno
- University of Tokyo , Tokyo , Japan
| | | | - Y Miyamoto
- National Cerebral and Cardiovascular Center Hospital , Osaka , Japan
| | - H Sato
- Precision K.K. , Tokyo , Japan
| | - R Nagai
- Jichi Medical University , Tochigi , Japan
| |
Collapse
|
5
|
Akashi N, Fujita H, Matoba T, Kohro T, Kabutoya T, Imai Y, Kario K, Kiyosue A, Nakayama M, Miyamoto Y, Nakamura T, Tsujita K, Matoba Y, Sato H, Nagai R. Hyperuricemia predicts worse prognosis in patients with chronic coronary syndrome after percutaneous coronary intervention: insights from Japanese real-world database using a storage system. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The relationship between hyperuricemia (HUA) and cardiovascular disease was observed in some epidemiological studies. However, the association between HUA and chronic coronary syndrome (CCS) after percutaneous coronary intervention (PCI) is not fully elucidated.
Purpose
The purpose of this study was to investigate the prognostic impact of HUA in patients with CCS after PCI.
Methods
This study is a retrospective, multicenter, observational study. We developed the Clinical Deep Data Accumulation System (CLIDAS), which consists of 6 university hospitals and the national cardiovascular center in Japan, directly obtains clinical data including patients background, laboratory data, echocardiogram, electrocardiogram, cardiac catheterization report, prescription, and long-term outcome from electronic medical records. A total of 9936 consecutive patients after PCI were analyzed. Of them, 5138 patients with CCS after PCI during April 2013 and March 2019 were analyzed, and divided into HUA group (patients with HUA at baseline, n=1724) and non-HUA group (patients without HUA at baseline, n=3414). HUA was defined as a serum uric acid levels ≥7.0 mg/dL for men or ≥6.0 mg/dL for women and/or taking urate-lowering drugs. The primary outcome was the major cardiovascular events (MACE) defined as being the composite of cardiovascular death, myocardial infarction, and hospitalization for heart failure.
Results
The median follow-up duration was 910 days (interquartile range: 307–1479 days). The proportion of male (78% vs. 78%) and age (71±11 vs. 71±10) were similar between the HUA and the non-HUA groups. The prevalence of hypertension (87% vs. 82%), atrial fibrillation (9% vs. 5%), and history of previous hospitalization for heart failure (15% vs. 6%) and baseline creatinine value (1.8±2.3 vs. 1.5±2.0 mg/dL) were significantly higher in the HUA group. In contrast, the prevalence of diabetes (43% vs. 48%) was significantly lower in the HUA group. The incidence of MACE was significantly higher in the HUA group than in the non-HUA group (13.1% vs. 6.4%, log rank P<0.001). Multivariate Cox regression analyses revealed that hyperuricemia was significantly associated with MACE (hazard ratio 1.50, 95% confidence interval 1.22–1.84, P<0.001) after controlling for other cardiovascular risk factors.
Conclusion
The real-world database CLIDAS revealed that hyperuricemia was significantly associated with the increase of MACE in patients with CCS after PCI. This result sheds light on the significant role of urate in prediction of prognosis, suggesting the possibility of new therapeutic approaches using urate-lowering drugs or SGLT2 inhibitors for the CCS patients.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Jichi Medical University, Tochigi, Japan, and Kowa Co., Ltd
Collapse
Affiliation(s)
- N Akashi
- Jichi Medical University Saitama Medical Center , Saitama , Japan
| | - H Fujita
- Jichi Medical University Saitama Medical Center , Saitama , Japan
| | - T Matoba
- Kyushu University Graduate School of Medical Sciences, Cardiovascular Medicine , Fukuoka , Japan
| | - T Kohro
- Jichi Medical University, Clinical Informatics , Tochigi , Japan
| | - T Kabutoya
- Jichi Medical University, Cardiovascular Medicine , Tochigi , Japan
| | - Y Imai
- Jichi Medical University, Clinical Pharmacology , Tochigi , Japan
| | - K Kario
- Jichi Medical University, Cardiovascular Medicine , Tochigi , Japan
| | - A Kiyosue
- University of Tokyo Hospital, Cardiovascular Medicine , Tokyo , Japan
| | - M Nakayama
- Tohoku University Graduate School of Medicine, Medical Informatics , Sendai , Japan
| | - Y Miyamoto
- National Cerebral and Cardiovascular Center Hospital, Open Innovation Center , Osaka , Japan
| | - T Nakamura
- Kumamoto University Hospital, Medical Informatics , Kumamoto , Japan
| | - K Tsujita
- Kumamoto University Hospital, Cardiovascular Medicine , Kumamoto , Japan
| | | | - H Sato
- Precision , Tokyo , Japan
| | - R Nagai
- Jichi Medical University , Tochigi , Japan
| |
Collapse
|
6
|
Nakahara T, Takemoto S, Houzawa H, Nakayama M. Desire for Alternative Treatment Options in Patients with Atopic Dermatitis in Japan: Results of a Web-Based Cross-Sectional Study (AD-JOIN Study). Dermatol Ther (Heidelb) 2022; 12:1383-1396. [PMID: 35583611 PMCID: PMC9209607 DOI: 10.1007/s13555-022-00738-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Accepted: 04/21/2022] [Indexed: 11/24/2022] Open
Abstract
INTRODUCTION Treatment satisfaction in patients with atopic dermatitis (AD) has been investigated in several studies, but the desire for alternative treatment options is unclear and has not been previously evaluated. We conducted a cross-sectional, web-based survey aimed at evaluating the desire for alternative treatment options in adults with AD from a patient registry in Japan. METHODS Main eligibility criteria were adults aged ≥ 18 years with AD who were receiving treatment with topical corticosteroids (TCS) and not systemic therapy. Questionnaires included the Patient Oriented Eczema Measure (POEM) and pruritus Numeral Rating Scale. The proportion of patients with a desire for an alternative treatment option was assessed, overall (Overall Desire) and by specific type of alternative treatment option (Specific Desire), including change in medication, hospital transfer, and complementary and alternative medicine (CAM) use. Patient background factors associated with desire were evaluated using multivariate logistic regression. RESULTS Of the 1500 patients included in the analysis, 91.5% (n = 1372) had an Overall Desire, with the most common Specific Desire being a change in medication (n = 1213, 80.9%), followed by CAM (n = 593, 39.5%) and hospital transfer (n = 429, 28.6%). Dissatisfaction with current treatment was significantly (p < 0.05) associated with Overall Desire and Specific Desire (p < 0.001 each). Severe disease according to POEM was significantly associated with Overall Desire and a change in medication (p < 0.001 each). CONCLUSIONS A high proportion of Japanese patients with AD being treated with TCS had a desire for alternative treatment options. The desire was greatly affected by patients' satisfaction with their current treatment and perception of disease severity. These findings highlight the importance of assessing patients' satisfaction or perception of disease severity, and facilitating early discussions between patient and doctor on their available treatment options, including new treatment options.
Collapse
Affiliation(s)
- Takeshi Nakahara
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| | - Shunya Takemoto
- Medical Department, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan.
| | - Hiroyuki Houzawa
- Medical Department, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan
| | - Masahiko Nakayama
- Medical Department, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan
| |
Collapse
|
7
|
Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, Morita Y, Eto T, Katsuoka Y, Takezako N, Uoshima N, Imada K, Ando J, Komeno T, Mori A, Ishikawa Y, Satake A, Watanabe J, Kawakami Y, Morita T, Taneike I, Nakayama M, Duan Y, Garbayo Guijarro B, Delgado A, Llamas C, Kiyoi H. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. Int J Hematol 2022; 116:89-101. [PMID: 35394258 DOI: 10.1007/s12185-022-03334-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 03/15/2022] [Accepted: 03/15/2022] [Indexed: 10/18/2022]
Abstract
Acute myeloid leukemia (AML) predominantly affects elderly adults, and its prognosis worsens with age. Treatment options for patients in Japan ineligible for intensive chemotherapy include cytarabine/aclarubicin ± granulocyte colony-stimulating factor (CA ± G), azacitidine (AZA), low-dose cytarabine (LDAC), targeted therapy, and best supportive care (BSC). The country's aging population and the evolving treatment landscape are contributing to a need to understand treatment pathways and associated outcomes. This retrospective chart review evaluated outcomes in patients across Japan with primary/secondary AML who were ineligible for intensive chemotherapy and began first-line treatment or BSC between 01/01/2015 and 12/31/2018. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and healthcare resource utilization (HRU). Of 199 patients (58% > 75 years), 121 received systemic therapy (38 CA ± G, 37 AZA, 7 LDAC, 39 other) and 78 received BSC. Median OS was 5.4, 9.2, 2.2, 3.8, and 2.2 months for CA ± G, AZA, LDAC, other systemic therapy, and BSC, respectively; median PFS was 3.4, 7.7, 1.6, 2.3, and 2.1 months, respectively. HRU rates were uniformly high, with > 80% patients hospitalized in each cohort. The poor clinical outcomes and high HRU among Japanese AML patients who are ineligible for intensive chemotherapy highlight an unmet need for novel therapies.
Collapse
Affiliation(s)
- Chikashi Yoshida
- Department of Hematology, National Hospital Organization Mito Medical Center, Ibaraki-machi, Japan.
| | - Takeshi Kondo
- Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
| | - Tomoki Ito
- First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
| | - Masahiro Kizaki
- Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| | | | - Toshihiro Miyamoto
- Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yasuyoshi Morita
- Division of Hematology and Rheumatology, Department of Internal Medicine, Kindai University, Osaka, Japan
| | - Tetsuya Eto
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
| | - Yuna Katsuoka
- Department of Hematology, Sendai Medical Center, National Hospital Organization, Sendai, Japan
| | - Naoki Takezako
- Department of Hematology, Disaster Medical Center, Tokyo, Japan
| | - Nobuhiko Uoshima
- Department of Hematology, Kyoto Second Red Cross Hospital, Kyoto, Japan
| | - Kazunori Imada
- Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan
| | - Jun Ando
- Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
| | - Takuya Komeno
- Department of Hematology, National Hospital Organization Mito Medical Center, Ibaraki-machi, Japan
| | - Akio Mori
- Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
| | - Yuichi Ishikawa
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Atsushi Satake
- First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
| | - Junichi Watanabe
- Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| | | | | | | | | | | | | | | | | | - Hitoshi Kiyoi
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
8
|
KIM J, Suzuki H, Kano T, Fukao Y, Nakayama M, Suzuki Y. POS-399 Anti-BAFF antibody is effective to inhibit the production of immunoglobulins, but not nephritogenic IgA in murine IgA nephropathy. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Oba Y, Kohro T, Sato H, Nochioka K, Nakayama M, Fujita H, Mizuno Y, Kiyosue A, Iwanaga Y, Miyamoto Y, Matoba T, Tsutsui H, Nakamura T, Usuku K, Nagai R. The relationships among the pulse rate, use of beta-blockers, and prognosis in patients with ischemic heart disease in a real-world database using a storage system. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The use of β-blockers has the effect of improving the prognosis of patients with ischemic heart disease (IHD). One of the underlying mechanisms is a decrease in the cardiac load due to a reduction in the heart rate.
Purpose
To clarify the relationships among the pulse rate, the use of β-blockers, and the prognosis in patients with IHD in a multicenter study using a storage system.
Methods
The Clinical Deep Data Accumulation System (CLIDAS) collects (1) basic patient information, prescriptions, and laboratory data from electronic medical records from the Standardized Structured Medical Information eXchange (SS-MIX2) standard storage, and (2) the results of physiological tests, cardiac catheterization, and cardiac catheter intervention reports from the SS-MIX2 extended storage. 8540 cases who underwent cardiac catheterization from 6 university hospitals and the national cardiovascular center in Japan were registered (male: 77%, average age: 70.2 years). We evaluated these patients' pulse rate at admission and at the discharge of cardiac catheterization in 6,598 patients. We divided the pulse rates at discharge into quartiles (Q1: <60, Q2: 60–66, Q3: 67–75, Q4: ≥76 bpm), and we analyzed the relationship between the pulse rate and the prognosis by dividing the patients into the stable angina group (n=2,631) and the acute coronary syndrome (ACS) group (n=2,394). Regarding the use of β-blockers, we compared the pulse rates of the patients taking carvedilol (n=1,728) and those taking bisoprolol (n=2,761) at admission and discharge. Major adverse cardiovascular events (MACE) were defined as cardiovascular death, non-fatal myocardial infarction, unstable angina, heart failure, stroke, and other hospitalized cardiovascular events.
Results
A total of 600 MACEs occurred during an average observation period of 890 days. The incidence of cardiovascular events was significantly higher in the Q4 patients in the stable angina group (hazard ratio 1.79, 95% confidence interval 1.32–2.41, but there was no significant difference among the four pulse rate subgroups in the ACS group. The bisoprolol-treated patients had lower pulse rates at discharge (67.4±12.2 vs. 68.8±11.8 bpm, p<0.001) and a lower percentage of patients in the Q4 group (21.2 vs. 24.9%, p=0.005) compared to the carvedilol-treated patients. The pulse rate at admission was similar in the bisoprolol- and carvedilol-treated patients (74.3±19.3 vs. 73.2±29.5 bpm, p=0.328).
Conclusion
In a real-world database using a storage system, a pulse rate of ≤75 bpm was associated with a good prognosis in patients with ACS. Compared to carvedilol, bisoprolol was associated with a decreased pulse rate at discharge.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Kowa Company, Ltd.
Collapse
Affiliation(s)
- Y Oba
- Jichi Medical University, Department of Internal Medicine, Tochigi, Japan
| | - T Kohro
- Jichi Medical University, Department of Internal Medicine, Tochigi, Japan
| | - H Sato
- Precision Inc., Tokyo, Japan
| | | | | | - H Fujita
- Jichi Medical University Saitama Medical Center, Saitama, Japan
| | - Y Mizuno
- University of Tokyo, Tokyo, Japan
| | | | - Y Iwanaga
- National Cerebral and Cardiovascular Center Hospital, Osaka, Japan
| | - Y Miyamoto
- National Cerebral and Cardiovascular Center Hospital, Osaka, Japan
| | - T Matoba
- Kyushu University, Fukuoka, Japan
| | | | | | - K Usuku
- Kumamoto University, Kumamoto, Japan
| | - R Nagai
- Jichi Medical University, Department of Internal Medicine, Tochigi, Japan
| |
Collapse
|
10
|
Matoba T, Fujita H, Kohro T, Kabutoya T, Kiyosue A, Mizuno Y, Nakayama M, Nochioka K, Miyamoto Y, Iwanaga Y, Tsujita K, Nakamura T, Sato H, Tsutsui H, Nagai R. Clinical Deep Data Accumulation System (CLIDAS) reveals lipid paradox in guideline-defined high risk Japanese patients after PCI. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Japanese clinical guidelines recommend a stratification of the risks and LDL-cholesterol (LDL-C) treatment goals for patients with coronary artery disease after percutaneous coronary intervention (PCI), i.e. <100 mg/dL for normal risk patients and <70 mg/dL for high risk patients; however, less is known about the association between baseline LDL-C values and long-term prognosis.
Purpose
To investigate the association between LDL-C goals and baseline LDL-C levels in relation to major adverse cardiovascular events (MACE) among high-risk patients after PCI, using a real-world database.
Methods
We developed the Clinical Deep Data Accumulation System (CLIDAS) that acquires clinical data directly from hospital information system, and implemented the system in 6 university hospitals and the national cardiovascular center in Japan. The CLIDAS database accumulates data regarding patient background, laboratory data, prescriptions, electrocardiogram, echocardiogram, PCI report, and long-term prognosis. We retrospectively analyzed 8540 consecutive patients who underwent PCI during April 2014 and March 2020 in participating hospitals, and classified them into the normal risk group (n=3712, 43%) and the high risk group [n=4828, 57%, with any of acute coronary syndrome (ACS), familial hypercholesterolemia (FH), or diabetes with additional risk factor(s)], for which LDL-C goals are <100 mg/dL and <70 mg/dL, respectively, according to the Japanese Atherosclerosis Society guidelines or the diagnosis and prevention of atherosclerotic cardiovascular diseases. The primary outcome was the time to first occurrence of MACE, a composite of cardiovascular death, stroke, myocardial infarction, and coronary revascularization in associations with baseline LDL-C levels and patient background.
Results
Proportion of male (77% vs. 77%) and age (71±11 vs. 70±11) were similar between 2 groups. The prevalence of ACS at the index PCI (0% vs. 62%), FH (0% vs. 2%), hypertension (61% vs. 86%), diabetes (11% vs. 67%), dyslipidemia (73% vs. 84%), hemodialysis (4% vs. 9%), peripheral artery disease (5% vs. 9%), smoking (16% vs. 30%), and prescription of statins (79% vs. 86%) were significantly higher in the high risk group. Among patients in the high risk group, but not in the normal risk group, baseline LDL-C <70 mg/dL was paradoxically associated with higher risk of MACE (P<0.0001 by Log-rank test) (Figure). The Cox proportional hazard model confirmed that the high risk group (risk ratio 1.54, 95% CI [1.31–1.81]), baseline LDL-C <70mg/dL (risk ratio 1.44, 95% CI [1.18–1.75]), baseline age (risk ratio 1.36, 95% CI [1.28–1.45] per 10 year), and prescription of statins (risk ratio 0.80, 95% CI [0.66–0.96]) were significantly associated with the risk of MACE in this population.
Conclusion
The CLIDAS real-world database revealed that baseline low LDL-C paradoxically associated with an increased risk of MACE among guideline-defined high risk patients after PCI.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Jichi Medical University, Tochigi, Japan, and Kowa
Collapse
Affiliation(s)
- T Matoba
- Kyushu University, Cardiovascular Medicine, Fukuoka, Japan
| | - H Fujita
- Jichi Medical University Saitama Medical Center, Cardiology, Saitama, Japan
| | - T Kohro
- Jichi Medical University, Medical Informatics, Tochigi, Japan
| | - T Kabutoya
- Jichi Medical University, Cardiology, Tochigi, Japan
| | - A Kiyosue
- University of Tokyo Hospital, Cardiology, Tokyo, Japan
| | - Y Mizuno
- University of Tokyo Hospital, Cardiology, Tokyo, Japan
| | - M Nakayama
- Tohoku University Graduate School of Medicine, Medical Informatics, Sendai, Japan
| | - K Nochioka
- Tohoku University Graduate School of Medicine, Medical Informatics, Sendai, Japan
| | - Y Miyamoto
- National Cerebral and Cardiovascular Center Hospital, Cerebral and Cardiovascular Disease Information, Osaka, Japan
| | - Y Iwanaga
- National Cerebral and Cardiovascular Center Hospital, Cerebral and Cardiovascular Disease Information, Osaka, Japan
| | - K Tsujita
- Kumamoto University Hospital, Cardiovascular Center, Kumamoto, Japan
| | - T Nakamura
- Kumamoto University Hospital, Medical Informatics, Kumamoto, Japan
| | | | - H Tsutsui
- Kyushu University, Cardiovascular Medicine, Fukuoka, Japan
| | - R Nagai
- Jichi Medical University, Tochigi, Japan
| | | |
Collapse
|
11
|
Okamura M, Konishi M, Saigusa Y, Ando S, Nakayama M, Komura N, Sugano T, Tamaura K, Nakamura T. Impact of grip strength and balance function on the exercise capacity in pulmonary hypertension. Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
【Background】
Patients with pulmonary hypertension (PH) suffer from poor exercise capacity due to impaired oxygenation or reduced cardiac output. However, the relationship between exercise capacity and physical functions remains unclear.
【Purpose】
The purpose of this study is to investigate the relationship between exercise capacity and physical functions in pulmonary hypertension.
【Methods】
From February 2018 to June 2020, 94 patients (61.3 ± 14.7 years old, 69.1% females) with group 1/3/4/5 PH underwent cardiac catheterization, 6-minute walking distance (6MWD), and physical function measurements simultaneously. The physical functions was measured using muscle strength (grip strength, knee extension muscle strength), balance function (one leg standing time), and short physical performance battery (SPPB). Exercise capacity was measured by 6MWD.
【Results】
The study cohort consists of 22/8/60/4 (23.4%/8.5%/63.8%/4.3%) patients with group 1/3/4/5 PH, respectively. The average age of each group was 50.7/64.7/63.1/66.0 years old, respectively. A total of 194 measurements of physical functions were evaluated from 94 patients and employed in multivariate logistic regression analysis using adaptive-LASSO methods with the 6MWD (476.2 ± 107.5m) as a dependent variable. WHO functional class (class II: standardized β=-0.35, 95% confidence interval (CI) [-0.54 - -0.16], p < 0.001), class III: β=-0.60, 95%CI [-0.90 - -0.30], p < 0.001), mixed venous oxygen saturation (SvO2: β=0.11, 95%CI [0.03 - 0.19], p = 0.008), pulmonary vascular resistance (PVR: β=-0.16, 95%CI [-0.25 - -0.07], p < 0.001), grip strength (β=0.20, 95%CI [0.09 - 0.31], p < 0.001), one leg standing time (β=0.10, 95%CI [0.00 - 0.20], p = 0.049) , and 4m gait speed test (β=-0.28, 95%CI [-0.36 - -0.19], p < 0.001) were associated with 6MWD.
【Conclusions】
Grip strength and balance function, as well as SvO2 and PVR, were associated with the exercise capacity in pulmonary hypertension.
Collapse
Affiliation(s)
- M Okamura
- Yokohama City University Hospital, Department of Rehabilitation, Yokohama, Japan
| | - M Konishi
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - Y Saigusa
- Yokohama City University School of Medicine, Department of Biostatistics, Yokohama, Japan
| | - S Ando
- Tokyo University of Science Faculty of Engineering, Department of Information and Computer Technology, Tokyo, Japan
| | - M Nakayama
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - N Komura
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - T Sugano
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Tamaura
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - T Nakamura
- Yokohama City University School of Medicine, Department of Rehabilitation Medicine, Yokohama, Japan
| |
Collapse
|
12
|
Nakayama M, Inoue R. Electronic phenotyping of heart failure from a national clinical information database. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
A database of clinical information collected from several medical institutions, including national university hospitals and private hospital groups, and the medical information database network, MID-NET, have been available to the public in Japan since 2018. To analyse clinical events, i.e., to perform electronic phenotyping, it is important to extract data from clinical information correctly, combine multiple pieces of information, and define the target disease. Herein, we investigated a study to find patients with heart failure and validated our findings using MID-NET data.
Methods
A criterion to describe heart failure cases was determined according to clinical guidelines released by the Japanese Circulation Society. The data studied were based on records from April 1–December 31, 2013. The initial rule was based on disease names, examinations, and medications pertaining to heart failure. We extracted and analysed clinical data from MID-NET and found patients with heart failure. Two doctors, including a cardiologist, reviewed the medical records and verified the legitimacy of the cases, following which we calculated precision and recall rates. Next, we examined a method to identify factors to extract true cases correctly using machine learning with XGBoost in R.
Results
A total of 5,282 cases extracted via disease names were related to heart failure. Of these, 2,799 cases corresponding to the initial rule were retrieved, and 200 cases were randomly sampled and assessed. A total of 70 cases were found to be true. Thus, a precision rate of 0.350 and a recall rate of 0.912 were determined. A machine learning method revealed the correlation of heart failure with several factors, including the serum b-type natriuretic peptide (BNP) value, link between commencement date of the disease and actual hospitalization date, and medications for the treatment of heart failure. Using this data, we could determine the conditions contributing to improving the validity of the cases with heart failure. In this manner, patient cases were extracted using the disease name as it is related to heart failure and hospitalisation within two weeks after the commencement date of the disease. Furthermore, the candidates were categorised into three groups according to serum BNP values (high, middle, and low ranges). The high group was labelled “heart failure”, and the low group was excluded. In the middle group, candidates were additionally categorised according to their prescribed medication for heart failure. Our analysis indicated that the precision rate increased to 0.878 while the recall rate decreased to 0.697. The F-measure also increased from 0.506 to 0.777.
Conclusions
To find target cases from a large clinical database, precise electronic phenotyping is required. A machine learning method can enable accurate identification of patients with heart failure. Leveraging large amounts of clinical data may be beneficial for medical research progress.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Japan Agency for Medical Research and Development
Collapse
Affiliation(s)
- M Nakayama
- Tohoku University Graduate School of Medicine, Medical Informatics, Sendai, Japan
| | - R Inoue
- Tohoku University Graduate School of Medicine, Medical Informatics, Sendai, Japan
| |
Collapse
|
13
|
Warisawa T, Cook C, Howard J, Nour D, Doi S, Nakayama M, Uetani T, Yamanaka F, Kikuta Y, Shiono Y, Nishina H, Matsuo H, Escaned J, Akashi Y, Davies J. Clinical outcomes of patients with diffuse coronary artery disease following physiology-guided treatment strategy: insights from AJIP registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Physiology-guided treatment strategy improves clinical outcomes of patients with coronary artery disease. However, it has not been fully evaluated whether such guideline-based strategy is useful for patients with diffuse coronary artery disease as well, which is known to be one of the major factors affecting morbidity and mortality.
Purpose
The aim of this study was to clarify clinical outcomes of patients with diffuse coronary artery disease whose treatment strategy was based on coronary physiology.
Methods
From an international multicentre registry of iFR-pullback, consecutive 1067 patients (1185 vessels) with stable angina were included in whom coronary lesions were deferred or revascularized according to the iFR cutoff: 0.89. The physiological pattern of disease was classified according to the iFR-pullback recording as predominantly physiologically diffuse (n=463) or predominantly physiologically focal (n=722). Major adverse cardiovascular events (MACEs), defined as a composite of cardiac death, non-fatal myocardial infarction, and ischemia-driven target lesion revascularization during follow-up period, were compared between diffuse and focal groups, in both deferred and revascularized groups, respectively.
Results
Mean age was 67.1±10.7 years and 75.8% of patients were men. Median iFR was 0.88 (interquartile range: 0.80 to 0.92). At a median follow-up period of 18 months, no significant differences in MACEs were found between diffuse and focal groups, in both iFR-based deferred and revascularized groups. In the deferred group (n=480), MACEs occurred in 6.9% patients (15/217) in the diffuse group and 8.0% patients (21/263) in the focal group (p=0.44). In the revascularized group (n=705), MACEs occurred in 8.9% patients (22/246) in the diffuse group and 7.2% patients (33/459) in the focal group (p=0.49).
Conclusions
Despite potentially higher risks in patients with diffuse coronary artery disease, clinical outcomes of those patients were comparable to those of patients without diffuse disease, as long as treatment strategy was based on the physiology guidance, which is globally recommended by international guidelines.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- T Warisawa
- St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan
| | - C.M Cook
- Imperial College London, Cardiovascular Science, London, United Kingdom
| | - J.P Howard
- Imperial College London, Cardiovascular Science, London, United Kingdom
| | - D Nour
- Imperial College London, Cardiovascular Science, London, United Kingdom
| | - S Doi
- St. Marianna University School of Medicine, Division of Cardiology, Kawasaki, Japan
| | - M Nakayama
- Toda Central General Hospital, Toda, Japan
| | | | - F Yamanaka
- Shonan Kamakura General Hospital, Kamakura, Japan
| | - Y Kikuta
- Fukuyama Cardiovascular Hospital, Fukuyama, Japan
| | - Y Shiono
- Wakayama Medical University, Wakayama, Japan
| | - H Nishina
- Tsukuba Medical Center Hospital, Tsukuba, Japan
| | | | - J Escaned
- Hospital Clinico San Carlos, Madrid, Spain
| | - Y.J Akashi
- St. Marianna University School of Medicine, Division of Cardiology, Kawasaki, Japan
| | - J.E Davies
- Imperial College London, Cardiovascular Science, London, United Kingdom
| |
Collapse
|
14
|
Noguchi R, Takahashi T, Kuroda K, Ochi M, Shirasawa T, Sakano M, Bareille C, Nakayama M, Watson MD, Yaji K, Harasawa A, Iwasawa H, Dudin P, Kim TK, Hoesch M, Kandyba V, Giampietri A, Barinov A, Shin S, Arita R, Sasagawa T, Kondo T. Publisher Correction: A weak topological insulator state in quasi-one-dimensional bismuth iodide. Nature 2020; 584:E4. [PMID: 32690939 DOI: 10.1038/s41586-020-2392-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Ryo Noguchi
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - T Takahashi
- Materials and Structures Laboratory, Tokyo Institute of Technology, Yokohama, Japan
| | - K Kuroda
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - M Ochi
- Department of Physics, Osaka University, Toyonaka, Japan
| | - T Shirasawa
- National Metrology Institute of Japan, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan
| | - M Sakano
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan.,Department of Applied Physics and Quantum-Phase Electronics Center (QPEC), The University of Tokyo, Tokyo, Japan
| | - C Bareille
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - M Nakayama
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - M D Watson
- Diamond Light Source, Harwell Campus, Didcot, UK
| | - K Yaji
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - A Harasawa
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - H Iwasawa
- Diamond Light Source, Harwell Campus, Didcot, UK.,Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Japan
| | - P Dudin
- Diamond Light Source, Harwell Campus, Didcot, UK
| | - T K Kim
- Diamond Light Source, Harwell Campus, Didcot, UK
| | - M Hoesch
- Diamond Light Source, Harwell Campus, Didcot, UK.,DESY Photon Science, Deutsches Elektronen-Synchrotron, Hamburg, Germany
| | - V Kandyba
- Elettra - Sincrotrone Trieste, Basovizza, Italy
| | | | - A Barinov
- Elettra - Sincrotrone Trieste, Basovizza, Italy
| | - S Shin
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan
| | - R Arita
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Japan
| | - T Sasagawa
- Materials and Structures Laboratory, Tokyo Institute of Technology, Yokohama, Japan.
| | - Takeshi Kondo
- Institute for Solid State Physics, University of Tokyo, Kashiwa, Japan.
| |
Collapse
|
15
|
Kuroda K, Arai Y, Rezaei N, Kunisada S, Sakuragi S, Alaei M, Kinoshita Y, Bareille C, Noguchi R, Nakayama M, Akebi S, Sakano M, Kawaguchi K, Arita M, Ideta S, Tanaka K, Kitazawa H, Okazaki K, Tokunaga M, Haga Y, Shin S, Suzuki HS, Arita R, Kondo T. Devil's staircase transition of the electronic structures in CeSb. Nat Commun 2020; 11:2888. [PMID: 32514054 PMCID: PMC7280508 DOI: 10.1038/s41467-020-16707-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 05/15/2020] [Indexed: 12/02/2022] Open
Abstract
Solids with competing interactions often undergo complex phase transitions with a variety of long-periodic modulations. Among such transition, devil's staircase is the most complex phenomenon, and for it, CeSb is the most famous material, where a number of the distinct phases with long-periodic magnetostructures sequentially appear below the Néel temperature. An evolution of the low-energy electronic structure going through the devil's staircase is of special interest, which has, however, been elusive so far despite 40 years of intense research. Here, we use bulk-sensitive angle-resolved photoemission spectroscopy and reveal the devil's staircase transition of the electronic structures. The magnetic reconstruction dramatically alters the band dispersions at each transition. Moreover, we find that the well-defined band picture largely collapses around the Fermi energy under the long-periodic modulation of the transitional phase, while it recovers at the transition into the lowest-temperature ground state. Our data provide the first direct evidence for a significant reorganization of the electronic structures and spectral functions occurring during the devil's staircase.
Collapse
Affiliation(s)
- Kenta Kuroda
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan.
| | - Y Arai
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - N Rezaei
- Department of Physics, Isfahan University of Technology, 84156-83111, Isfahan, Iran
| | - S Kunisada
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - S Sakuragi
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - M Alaei
- Department of Physics, Isfahan University of Technology, 84156-83111, Isfahan, Iran
| | - Y Kinoshita
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - C Bareille
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - R Noguchi
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - M Nakayama
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - S Akebi
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - M Sakano
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
- Department of Applied Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - K Kawaguchi
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - M Arita
- Hiroshima Synchrotron Center, Hiroshima University, Higashi-Hiroshima, 739-0046, Japan
| | - S Ideta
- UVSOR Facility, Institute for Molecular Science, Okazaki, 444-8585, Japan
| | - K Tanaka
- UVSOR Facility, Institute for Molecular Science, Okazaki, 444-8585, Japan
| | - H Kitazawa
- National Institute for Materials Science, 1-2-1 Sengen, Tsukuba, 305-0047, Japan
| | - K Okazaki
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - M Tokunaga
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - Y Haga
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki, 319-1195, Japan
| | - S Shin
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - H S Suzuki
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
| | - R Arita
- Department of Applied Physics, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
- RIKEN Center for Emergent Matter Science (CEMS), 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Takeshi Kondo
- ISSP, University of Tokyo, Kashiwa, Chiba, 277-8581, Japan
- Trans-scale Quantum Science Institute, University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
| |
Collapse
|
16
|
Sato J, Nakayama M, Tomita A, Sonoda T, Miyamoto T. Difference in the antibacterial action of epigallocatechin gallate and theaflavin 3,3'-di-O-gallate on Bacillus coagulans. J Appl Microbiol 2020; 129:601-611. [PMID: 32281733 DOI: 10.1111/jam.14662] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 03/11/2020] [Accepted: 03/29/2020] [Indexed: 11/28/2022]
Abstract
AIMS To study the mechanism of the antibacterial action of tea polyphenols such as catechins and theaflavins against Bacillus coagulans, and the interaction of epigallocatechin gallate (EGCg) or theaflavin 3,3'-di-O-gallate (TFDG) with the surface of B. coagulans cells was investigated. METHODS AND RESULTS The antibacterial activities of EGCg and TFDG against B. coagulans cells were measured by counting of the viable cells after the mixing with each polyphenol. Bactericidal effect of TFDG was shown at the concentration of greater than or equal to 62·5 mg l-1 ; however, at the same concentration, EGCg did not. According to the results of two dimensional (2D)-electrophoresis analysis, TFDG seemed to interact with cytoplasmic membrane proteins. The activity of the glucose transporters of the cells decreased 40% following the treatment with TFDG of 62·5 mg l-1 ; however, this decrease was only slight in case of EGCg. This result was in accordance with the strength of their bactericidal activities. CONCLUSION Our results suggest that the direct interaction between membrane proteins and TFDG is an important factor in the antibacterial activity of polymerized catechins, affecting their functions and leading to cell death. SIGNIFICANCE AND IMPACT OF THE STUDY Tea polyphenols can effectively use the prevention of product spoilage in the food and beverage industry.
Collapse
Affiliation(s)
- J Sato
- Safety Science Research, R&D, Kao Corporation, Ichikai, Tochigi, Japan.,Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Nishi-ku, Fukuoka, Japan
| | - M Nakayama
- Safety Science Research, R&D, Kao Corporation, Ichikai, Tochigi, Japan
| | - A Tomita
- Safety Science Research, R&D, Kao Corporation, Ichikai, Tochigi, Japan
| | - T Sonoda
- Safety Science Research, R&D, Kao Corporation, Ichikai, Tochigi, Japan
| | - T Miyamoto
- Division of Food Science & Biotechnology, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, Nishi-ku, Fukuoka, Japan
| |
Collapse
|
17
|
Sakano M, Hirayama M, Takahashi T, Akebi S, Nakayama M, Kuroda K, Taguchi K, Yoshikawa T, Miyamoto K, Okuda T, Ono K, Kumigashira H, Ideue T, Iwasa Y, Mitsuishi N, Ishizaka K, Shin S, Miyake T, Murakami S, Sasagawa T, Kondo T. Radial Spin Texture in Elemental Tellurium with Chiral Crystal Structure. Phys Rev Lett 2020; 124:136404. [PMID: 32302163 DOI: 10.1103/physrevlett.124.136404] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 02/10/2020] [Indexed: 06/11/2023]
Abstract
The chiral crystal is characterized by a lack of mirror symmetry and inversion center, resulting in the inequivalent right- and left-handed structures. In the noncentrosymmetric crystal structure, the spin and momentum of electrons are expected to be locked in the reciprocal space with the help of the spin-orbit interaction. To reveal the spin textures of chiral crystals, we investigate the spin and electronic structure in a p-type semiconductor, elemental tellurium, with the simplest chiral structure by using spin- and angle-resolved photoemission spectroscopy. Our data demonstrate that the highest valence band crossing the Fermi level has a spin component parallel to the electron momentum around the Brillouin zone corners. Significantly, we have also confirmed that the spin polarization is reversed in the crystal with the opposite chirality. The results indicate that the spin textures of the right- and left-handed chiral crystals are hedgehoglike, leading to unconventional magnetoelectric effects and nonreciprocal phenomena.
Collapse
Affiliation(s)
- M Sakano
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - M Hirayama
- Department of Physics, Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
- Tokodai Institute for Element Strategy (TIES), Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - T Takahashi
- Materials and Structures Laboratory (MSL), Tokyo Institute of Technology, Yokohama, Kanagawa 226-8503, Japan
| | - S Akebi
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - M Nakayama
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - K Kuroda
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - K Taguchi
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Hiroshima 739-8526, Japan
| | - T Yoshikawa
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Hiroshima 739-8526, Japan
| | - K Miyamoto
- Hiroshima Synchrotron Radiation Center (HiSOR), Hiroshima University, Higashi-Hiroshima, Hiroshima 739-0046, Japan
| | - T Okuda
- Hiroshima Synchrotron Radiation Center (HiSOR), Hiroshima University, Higashi-Hiroshima, Hiroshima 739-0046, Japan
| | - K Ono
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Kumigashira
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- Institute of Multidisciplinary Research for Advanced Materials (IMRAM), Tohoku University, Sendai 980-8577, Japan
| | - T Ideue
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - Y Iwasa
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - N Mitsuishi
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
| | - K Ishizaka
- Quantum-Phase Electronics Center (QPEC) and Department of Applied Physics, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - S Shin
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
| | - T Miyake
- Research Center for Computational Design of Advanced Functional Materials (CD-FMat), AIST, Tsukuba, Ibaraki 305-8568, Japan
| | - S Murakami
- Department of Physics, Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
- Tokodai Institute for Element Strategy (TIES), Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8551, Japan
| | - T Sasagawa
- Materials and Structures Laboratory (MSL), Tokyo Institute of Technology, Yokohama, Kanagawa 226-8503, Japan
| | - Takeshi Kondo
- Institute for Solid State Physics (ISSP), The University of Tokyo, Kashiwa 277-8581, Japan
- AIST-UTokyo Advanced Operando-Measurement Technology Open Innovation Laboratory (OPERANDO-OIL), Kashiwa, Chiba 277-8581, Japan
- Trans-scale Quantum Science Institute, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
18
|
Nour D, Shun-shin M, Fung M, Howard J, Ahmed Y, Allahwala U, Alzuhairi K, Bhindi R, Chamie D, Cook C, Doi S, Funayama N, Hansen P, Horinaka R, Ishibashi Y, Hijikata N, Kaihara T, Kawase Y, Koga M, Kotecha T, Kuwata S, Manica A, Matsuo H, Nakayama M, Nijjer S, Petraco R, Rajkumar C, Ramrakha P, Ruparelia N, Seligman H, Sen S, Takahashi T, Tanabe Y, Warisawa T, Watanabe A, Weaver J, Yong T, Francis D, Al-Lamee R. 834 How Accurately can Physicians Predict Invasive Physiology Using Coronary Angiography? Results of an International Multi-Centre Survey. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Mihara T, Fukui A, Arima S, Sato S, Nakayama M. Relationship between meniere's disease and sleep dynamics. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Kondo T, Kimura M, Nakayama M, Matsuda O. P1259Right atrial low voltage zone as a novel predictor of sinus node dysfunction in patients with non-paroxysmal atrial fibrillation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Although sinus node dysfunction (SND) coexists with atrial fibrillation (AF) in some cases, SND in patients with Non-paroxysmal AF (Non-PAF) could not be estimated in conventional electrophysiological study.
Atrial low voltage zone (LVZ), which may be surrogate for atrial fibrosis, is although reported to present in patients with Non-PAF, the association between SND and right atrial LVZ (RA-LVZ) has not been fully evaluated. The aim of the present study was to assess the relationship between SND and RA-LVZ in patients with Non-PAF.
Method
Eighty-six Non-PAF patients underwent high density voltage mapping of right atrium (RA) during AF before ablation procedure. We defined LVZ as that with electrogram amplitude <0.1 mV in order to delineate strongly damaged area in RA. We evaluated the surface are of the RA-LVZ in Non-PAF patients with and without SND.
Results
Twenty-seven of 86 patients (31.4%) presented with SND after AF termination. There were no significant differences between patients with and without SND in variables such as age, sex, AF duration, left atrial diameter, and left ventricular ejection fraction. The mean value of RA-LVZ of all the patients was 12.1±11.4%, and RA-LVZ was significantly larger in patients with SND than in those without SND (22.8±14.6 vs 7.2±4.2%; P<0.001). In multivariate logistic regression analysis for the incidence of subsequent pacemaker implantation (PMI), only RA-LVZ was a significant predictor of subsequent PMI (odd ratio 1.306; 95% confidence interval 1.159 - 1.473; P<0.001). Receiving-operating characteristic curve for PMI following ablation procedure indicated cut-off value 10.5% for RA-LVZ with 85.2% sensitivity and 88.1% specificity (area under curve = 0.924, P<0.001). Kaplan-Meier analysis of the incidence of PMI after AF termination showed that freedom from pacemaker implantation was significantly better in patients with RA-LVA <10.5% than in those with RA-LVZ ≥10.5% (log-rank test; P<0.001).
Conclusions
Broad RA-LVZ measured during AF was strongly associated with SND and PMI after AF termination in patients with Non-PAF. Evaluation of RA-LVZ during AF could be a potential target in predicting SND requiring PMI in patients with Non-PAF.
Collapse
Affiliation(s)
- T Kondo
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| | - M Kimura
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| | - M Nakayama
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| | - O Matsuda
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| |
Collapse
|
21
|
Ohyanagi F, Nagai Y, Kasai T, Koyama N, Kobayashi K, Hoshi E, Nakayama M, Mori K. P2.01-95 Updated Data of KRSG 1302 Study: Nedaplatin and Nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
TAKI F, Nakayama M, Hoshino E. SUN-251 A NEW SIMPLE SCORING MODEL FOR PREDICTING ESRD WITHIN A YEAR. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
23
|
YAMAMOTO T, Miyazaki M, Nakayama M, Sato H, Ito S. SUN-262 CAUSE OF DEATH IN JAPANESE PATIENTS WITH CHRONIC KIDNEY DISEASE: THE GONRYO STUDY. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
24
|
Okizaki A, Nakayama M. P279An investigation for quantitative myocardial blood flow with Tc-99m MIBI by a graph plot analysis in rat with and without propranolol administration. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez148.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Okizaki
- Asahikawa Medical University, Asahikawa, Japan
| | - M Nakayama
- Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
25
|
Cohen I, Zhao D, Menon G, Nakayama M, Koseki H, Zheng D, Ezhkova E. 287 Polycomb repressive complex 1 (PRC1) preserves epidermal tissue integrity independently of PRC2. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Kobayashi S, Inoue Y, Fujita F, Ito S, Yamaguchi I, Nakayama M, Kanetaka K, Takatsuki M, Eguchi S. Extent of intraluminal exfoliated malignant cells during surgery for colon cancer: Differences in cell abundance ratio between laparoscopic and open surgery. Asian J Endosc Surg 2019; 12:145-149. [PMID: 29992749 DOI: 10.1111/ases.12617] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Revised: 05/16/2018] [Accepted: 05/21/2018] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Laparoscopic colectomy with intracorporeal anastomosis is a minimally invasive surgical procedure for patients with colon cancer. However, there are often concerns about the presence of intraluminal exfoliated malignant cells in the intracorporeal anastomosis. This study investigated the relationship between colon cancer surgery and the incidence of intraluminal exfoliated malignant cells and several factors. METHODS Eighty-nine consecutive patients who underwent either laparoscopic or open colectomy were prospectively studied in our department between 2007 and 2011. Before anastomosis, the proximal and distal lumens were irrigated with normal saline and subjected to cytological examination. RESULTS In 27 patients (30.3%), exfoliated cancer cells were detected. On the distal side, the frequency of positive cytology findings of exfoliated malignant cells was significantly lower in the laparoscopic colectomy group than in the open colectomy group (P = 0.01). In the laparoscopic colectomy group, there were no cases of positive cytology findings for exfoliated malignant cells more than 100 mm from the primary tumor. The incidence of positive cytology more than 100 mm from the primary tumor was significantly lower than the incidence of positive cytology less than 100 mm from the primary tumor (P = 0.04). CONCLUSIONS Exfoliated malignant cells were detected at anastomosis sites in patients with colon cancer. On the distal side, laparoscopic colectomy may prevent the development of exfoliated malignant cells.
Collapse
Affiliation(s)
- Shinichiro Kobayashi
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Yusuke Inoue
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Fumihiko Fujita
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Shinichiro Ito
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Izumi Yamaguchi
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Masahiko Nakayama
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Kengo Kanetaka
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Mitsuhisa Takatsuki
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Susumu Eguchi
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| |
Collapse
|
27
|
Noguchi R, Takahashi T, Kuroda K, Ochi M, Shirasawa T, Sakano M, Bareille C, Nakayama M, Watson MD, Yaji K, Harasawa A, Iwasawa H, Dudin P, Kim TK, Hoesch M, Kandyba V, Giampietri A, Barinov A, Shin S, Arita R, Sasagawa T, Kondo T. A weak topological insulator state in quasi-one-dimensional bismuth iodide. Nature 2019; 566:518-522. [DOI: 10.1038/s41586-019-0927-7] [Citation(s) in RCA: 80] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 11/24/2018] [Indexed: 11/09/2022]
|
28
|
Sugiyama T, Kasai T, Koyama N, Kobayashi K, Hoshi E, Nakayama M, Mori K. A phase II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer (KRSG1302). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Nakayama M. P5727There are gender differences in plasma aldosterone concentration/plasma renin activity ratio in hypertensive patients without adenoma of adrenal gland. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Nakayama
- Nakayama Cardiocascular Clinic, Cardiology, Amakusa City, Japan
| |
Collapse
|
30
|
Kondo T, Kimura M, Nakayama M, Matsuda O. P6593Atrial low voltage zone as a novel predictor of sinus node dysfunction in patients with persistent atrial fibrillation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Kondo
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| | - M Kimura
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| | - M Nakayama
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| | - O Matsuda
- Hiroshima Heart Center, Department of Cardiology, Hiroshima, Japan
| |
Collapse
|
31
|
Nakayama M, Kobayashi H, Okazaki M, Imanaka K, Yoshizawa K, Mahlich J. Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan. Am J Mens Health 2018; 12:1094-1101. [PMID: 29774804 PMCID: PMC6131454 DOI: 10.1177/1557988318776123] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Revised: 04/09/2018] [Accepted: 04/13/2018] [Indexed: 12/29/2022] Open
Abstract
The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute. A total of 103 PCa patients and 127 physicians responded. The study looked at 37 patients considered as advanced PCa and 66 who were non-advanced PCa. All of the physicians were urologists. Advanced PCa patients ranked the attributes as follows: treatment effectiveness (RI: 32%), accessibility of treatment (RI: 26%), QOL (RI: 23%), and side effects (RI: 19%). For physicians, the RI ranking was the same as for advanced PCa patients; treatment effectiveness (RI: 29%), accessibility of treatment (RI: 27%), QOL (RI: 26%), and side effects (RI: 18%). For non-advanced PCa patients, accessibility of treatment ranked the highest RI (27%) and treatment effectiveness ranked as the lowest RI (14%). Our study suggests that the ranking of the attributes was consistent between advanced PCa patients and physicians. The most influential attribute was treatment effectiveness. Treatment preferences also vary by disease stage.
Collapse
Affiliation(s)
| | | | - Masateru Okazaki
- Medical Affairs Division, Janssen
Pharmaceutical K.K., Tokyo, Japan
| | - Keiichiro Imanaka
- Research and Development Division, Janssen
Pharmaceutical K.K., Tokyo, Japan
| | | | - Jörg Mahlich
- Health Economics Division, Janssen
Pharmaceutical K.K., Tokyo, Japan
- Düsseldorf Institute for Competition Economics
(DICE), University of Düsseldorf, Germany
| |
Collapse
|
32
|
Nakayama M, Teramoto Y, Sasayama R, Tsuda K, Matsuda A, Sakai Y. Six-month effectiveness of low-frequency repetitive transcranial magnetic stimulation and intensive occupational therapy in upper limb hemiparesis after stroke. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Naito Y, Kawahara A, Okabe Y, Ishida Y, Sadashima E, Murata K, Takase Y, Abe H, Yamaguchi T, Tanigawa M, Mihara Y, Kondo R, Kusano H, Nakayama M, Shimamatsu K, Yano H, Akiba J. SurePath ® LBC improves the diagnostic accuracy of intrahepatic and hilar cholangiocarcinoma. Cytopathology 2018; 29:349-354. [PMID: 29723910 DOI: 10.1111/cyt.12565] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/03/2018] [Indexed: 01/22/2023]
Abstract
INTRODUCTION The current study aimed to compare cytology using SurePath® (SP)-LBC and biliary tissue histology (BTH) for the diagnosis of biliary disease. METHODS Between January 2014 and December 2016, 57 patients underwent endoscopic retrograde cholangiopancreatography for the diagnosis of biliary disease. Biliary cytological samples were processed using SP-LBC and subsequently BTH was performed. A final diagnosis was confirmed by surgery (23 malignant cases) and clinical follow-up (34 benign and malignant cases): 18 extrahepatic cholangiocarcinoma; 17 intrahepatic/hilar cholangiocarcinoma (intra/H-CC); eight other malignant disease; and 14 benign biliary disease. The diagnoses made using SP-LBC and BTH were classified into four categories: (1) benign; (2) indeterminate; (3) suspicious for malignancy/malignant; and (4) inadequate. In addition, diagnostic accuracy was compared between SP-LBC and BTH. RESULTS Although 23% (13/57) of BTH samples were classified as inadequate, all SP-LBC cases were classified as adequate. Among 43 malignant cases, 11 normal, four indeterminate and 28 suspicious for malignancy/malignant were found using SP-LBC (26%, 9% and 65%, respectively), in contrast to 10 inadequate, nine normal, 10 indeterminate and 14 suspicious for malignancy/malignant observed using BTH (23%, 21%, 23%, and 33%, respectively). The identification of malignant cells was strikingly different between SP-LBC and BTH. Furthermore, limited to intra/H-CC, accuracy was significantly higher using SP-LBC than using BTH (P < .001). CONCLUSIONS SP-LBC of the biliary tract is a useful and reliable method for diagnosing biliary malignant disease and has an advantage over BTH for detecting malignant cells and accurately diagnosing intra/H-CC.
Collapse
Affiliation(s)
- Y Naito
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.,Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - A Kawahara
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
| | - Y Okabe
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
| | - Y Ishida
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
| | - E Sadashima
- Shin-Koga Hospital, Medical Corporation Tenjinkai, Kurume, Japan
| | - K Murata
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
| | - Y Takase
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
| | - H Abe
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
| | - T Yamaguchi
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
| | - M Tanigawa
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - Y Mihara
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - R Kondo
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - H Kusano
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - M Nakayama
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - K Shimamatsu
- Department of Pathology, Omuta City Hospital, Omuta, Japan
| | - H Yano
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | - J Akiba
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan
| |
Collapse
|
34
|
Cheung S, Hamuro Y, Mahlich J, Nakayama M, Tsubota A. Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data. PLoS One 2018; 13:e0195789. [PMID: 29694373 PMCID: PMC5919000 DOI: 10.1371/journal.pone.0195789] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 03/29/2018] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Limited availability of real-world data that describe treatment patterns of Japanese prostate cancer (PCA) patients. METHODS A biweekly transition analysis of PCA treatment was performed for patients with PCA diagnosis and a specific treatment between 2010 and 2015. To account for different cancer stages, two patient populations were analyzed. The first group consisted of patients on medication for hormone-sensitive prostate cancer (HSPC). The second group is comprised of patients who ended up receiving specific therapy for castration-resistant prostate cancer (CRPC). For each treatment, the average of treatment duration and the portion of patients transitioning to a consecutive treatment was calculated. RESULTS We identified 59,626 patients from the Japanese administrative database with a PCA diagnosis and specific treatment. In the first year of our observational study 786 patients commenced a HSPC treatment and 695 received a CRPC specific therapy Among the HSPC group, we found that combination hormonal therapy, comprised of a gonadotrophin releasing hormone agonist or antagonist with an antiandrogen was more common than monotherapy. The results of the CRPC group indicated that chemotherapy administration was for a shorter time period in a real-world setting as compared to published clinical studies. CONCLUSION Utilizing a novel method to visualize real-world treatment pathways for PCA patients we found that real treatment pathways are in line with international guidelines.
Collapse
Affiliation(s)
| | | | - Jörg Mahlich
- Janssen KK, Health Economics, Tokyo, Japan
- DICE, University of Dusseldorf, Dusseldorf, Germany
| | | | | |
Collapse
|
35
|
Nakatsu H, Maniwa A, Kamiya N, Ogi M, Kobayashi H, Nakayama M. PD10-08 ABIRATERONE ACETATE (AA) + PREDNISOLONE (P) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WITH EARLY PROGRESSION OR NO-RESPONSE TO ANDROGEN DEPRIVATION THERAPY (ADT); FINAL ANALYSIS. J Urol 2018. [DOI: 10.1016/j.juro.2018.02.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
Kobayashi S, Kanetaka K, Nagata Y, Nakayama M, Matsumoto R, Takatsuki M, Eguchi S. Predictive factors for major postoperative complications related to gastric conduit reconstruction in thoracoscopic esophagectomy for esophageal cancer: a case control study. BMC Surg 2018; 18:15. [PMID: 29510754 PMCID: PMC5838941 DOI: 10.1186/s12893-018-0348-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Accepted: 02/23/2018] [Indexed: 12/22/2022] Open
Abstract
Background Regardless of developments in thoracoscopic esophagectomy (TE), postoperative complications relative to gastric conduit reconstruction are common after esophagectomy. The aim of the present study was to evaluate the predictive factors of major complications related to gastric conduit after TE. Methods From 2006 to 2015, 75 patients with esophageal cancer who underwent TE were evaluated to explore the predictive factors of major postoperative complications related to gastric conduit. Results Patients with major complications related to gastric conduit had a significantly longer postoperative hospital stay than patients without these complications (P < 0.01). Multivariate analysis demonstrated that three-field lymph node dissection (3FLND) and high serum levels of creatine phosphokinase (CPK) and C-reactive protein (CRP) at 1 postoperative day (1POD) after TE were significant predictive factors of major complications related to gastric conduit [odds ratio (OR) 5.37, 95% confidence interval (CI) 1.41–24.33, P = 0.02; OR 5.40, 95% CI 1.60–20.20, P < 0.01; OR 5.07, 95% CI 1.47–20.25, P = 0.01, respectively]. The incidence rates of major complications related to gastric conduit for 0, 1, 2, and 3 predictive factors were 5.3%, 18.8%, 58.8%, and 85.7%, respectively (P < 0.01). Conclusions Two or more factors in 3FLND and the high levels of CPK and CRP at 1POD after TE were identified as the risk model for major complications related to gastric conduit after TE. Trial registration UMIN Clinical Trials Registry, ID: UMIN000024436, Registered date: Oct/17/2016.
Collapse
Affiliation(s)
- Shinichiro Kobayashi
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan
| | - Kengo Kanetaka
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan
| | - Yasuhiro Nagata
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan.,Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-12-4, Nagasaki, Japan
| | - Masahiko Nakayama
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan
| | - Ryo Matsumoto
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan
| | - Mitsuhisa Takatsuki
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan
| | - Susumu Eguchi
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki, 8528102, Japan.
| |
Collapse
|
37
|
Bolt T, Mahlich J, Nakamura Y, Nakayama M. Hematologists' Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment. Clin Ther 2018; 40:296-308.e2. [PMID: 29358004 DOI: 10.1016/j.clinthera.2017.12.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 12/06/2017] [Accepted: 12/18/2017] [Indexed: 01/24/2023]
Abstract
PURPOSE With the progress being made in the treatment of multiple myeloma and other complex cancers, a variety of clinical research and treatment options are being pursued. This study uses a discrete choice experiment (DCE) to estimate treatment characteristic preferences of hematologists in Japan. METHODS A 2-stage process was applied within this study. The first stage is an attribute-rating exercise in which each of the full list of 21 attributes is rated on its importance by the clinicians when selecting a first-line therapy. The top 8 rated attributes from a stepwise logistic regression model are then used to develop a DCE to estimate hematologists' willingness to trade-off characteristics of the treatment options in their recommendation of a first-line treatment. A logit model was used to identify the attribute levels that were the strongest determinants of the physicians' treatment preferences. FINDINGS From among the potential treatment attributes presented, improved overall survival had the most significant impact on the treatment choice of participating Japanese hematologists. Improvement in the ability to promptly reduce M-protein is also a highly prioritized treatment characteristic, with hematologists willing to sacrifice just over 1 month extra overall survival for this. Additionally, the hematologists' value improved suitability for chromosomal abnormalities with poor prognosis, suitability of the mechanism of action in initial treatment, and promptly improving calcium-renal-anemia-bone symptoms each at roughly 0.9 months extended overall survival. The reduction of adverse events is among the other significant factors in choice of treatment, though it was not found to be as strong a determinant as those mentioned. IMPLICATIONS This study reinforces the expectation that clinical research and treatment options should continue to focus on overall survival and are key priorities in multiple myeloma treatment development. However, clinicians are willing to consider and trade off other clinical factors and markers in their choice of treatment. The potential improvements presented were also found to have a greater impact on treatment choice than aversion to the potential worse outcomes presented.
Collapse
Affiliation(s)
- Timothy Bolt
- Faculty of Economics, Saitama University, Saitama, Japan
| | - Jörg Mahlich
- Health Economics, Janssen KK, Tokyo, Japan; Düsseldorf Institute for Competition Economics, University of Düsseldorf, Düsseldorf, Germany.
| | | | | |
Collapse
|
38
|
Yamada G, Oguri T, Ueki Y, Oishi N, Fukui A, Nakayama M, Matsukawa N. Striatal dysfunction and diminished functional connectivity in idiopathic REM sleep behavior disorder with subtle motor alteration. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.1036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Kuroda K, Tomita T, Suzuki MT, Bareille C, Nugroho AA, Goswami P, Ochi M, Ikhlas M, Nakayama M, Akebi S, Noguchi R, Ishii R, Inami N, Ono K, Kumigashira H, Varykhalov A, Muro T, Koretsune T, Arita R, Shin S, Kondo T, Nakatsuji S. Evidence for magnetic Weyl fermions in a correlated metal. Nat Mater 2017; 16:1090-1095. [PMID: 28967918 DOI: 10.1038/nmat4987] [Citation(s) in RCA: 115] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Accepted: 08/21/2017] [Indexed: 06/07/2023]
Abstract
Weyl fermions have been observed as three-dimensional, gapless topological excitations in weakly correlated, inversion-symmetry-breaking semimetals. However, their realization in spontaneously time-reversal-symmetry-breaking phases of strongly correlated materials has so far remained hypothetical. Here, we report experimental evidence for magnetic Weyl fermions in Mn3Sn, a non-collinear antiferromagnet that exhibits a large anomalous Hall effect, even at room temperature. Detailed comparison between angle-resolved photoemission spectroscopy (ARPES) measurements and density functional theory (DFT) calculations reveals significant bandwidth renormalization and damping effects due to the strong correlation among Mn 3d electrons. Magnetotransport measurements provide strong evidence for the chiral anomaly of Weyl fermions-namely, the emergence of positive magnetoconductance only in the presence of parallel electric and magnetic fields. Since weak magnetic fields (approximately 10 mT) are adequate to control the distribution of Weyl points and the large fictitious fields (equivalent to approximately a few hundred T) produced by them in momentum space, our discovery lays the foundation for a new field of science and technology involving the magnetic Weyl excitations of strongly correlated electron systems such as Mn3Sn.
Collapse
Affiliation(s)
- K Kuroda
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - T Tomita
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
| | - M-T Suzuki
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
- RIKEN Center for Emergent Matter Science (CEMS), 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - C Bareille
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - A A Nugroho
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
- Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Jl. Ganesha 10, 40132 Bandung, Indonesia
| | - P Goswami
- Condensed Matter Theory Center and Joint Quantum Institute, Department of Physics, University of Maryland, College Park, Maryland 20742- 4111, USA
- Department of Physics and Astronomy, 2145 Sheridan Road, Evanston, Illinois 60208, USA
| | - M Ochi
- Department of Physics, Osaka University, Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan
| | - M Ikhlas
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
| | - M Nakayama
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - S Akebi
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - R Noguchi
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - R Ishii
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - N Inami
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Ono
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Kumigashira
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - A Varykhalov
- Helmholtz-Zentrum Berlin für Materialien und Energie, Elektronenspeicherring BESSY II, Albert-Einstein-Strasse 15, 12489 Berlin, Germany
| | - T Muro
- Japan Synchrotron Radiation Research Institute (JASRI), 1-1-1 Kouto, Sayo, Hyogo 679-5198, Japan
| | - T Koretsune
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
- RIKEN Center for Emergent Matter Science (CEMS), 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - R Arita
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
- RIKEN Center for Emergent Matter Science (CEMS), 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Shin
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - Takeshi Kondo
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
| | - S Nakatsuji
- Institute for Solid State Physics, University of Tokyo, Kashiwa 277-8581, Japan
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
| |
Collapse
|
40
|
Yamada G, Ueki Y, Oguri T, Oishi N, Fukui A, Nakayama M, Matsukawa N. Nigrostriatal degeneration and altered corticostriatal functional connectivity in REM sleep behavior disorder with subtle motor dysfunction. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Villasante A, Sakaguchi K, Kim J, Cheung N, Nakayama M, Parsa H, Okano T, Shimizu T, Vunjak-Novakovic G. Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma. Am J Cancer Res 2017; 7:4099-4117. [PMID: 29158813 PMCID: PMC5695000 DOI: 10.7150/thno.20730] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Accepted: 08/11/2017] [Indexed: 01/26/2023] Open
Abstract
Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG. Tumor relapse is the major cause of succumbing to this disease, and properties attributed to cancer stem-like cells (CSLC), such as drug-resistance and cell plasticity, seem to be the key mechanisms. However, the lack of controllable models that recapitulate the features of human neuroblastoma limits our understanding of the process and impedes the development of new therapies. In response to these limitations, we engineered a perfusable, vascularized in vitro model of three-dimensional human neuroblastoma to study the effects of retinoid therapy on tumor vasculature and drug-resistance. METHODS The in vitro model of neuroblastoma was generated using cell-sheet engineering and cultured in a perfusion bioreactor. Firstly, we stacked three cell sheets containing SKNBE(2) neuroblastoma cells and HUVEC. Then, a vascular bed made of fibrin, collagen I and HUVEC cells was placed onto a collagen-gel base with 8 microchannels. After gelling, the stacked cell sheets were placed on the vascular bed and cultured in the perfusion bioreactor (perfusion rate: 0.5 mL/min) for 4 days. Neuroblastoma models were treated with 10μM isotretionin in single daily doses for 5 days. RESULTS The bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG. Treatment with Isotretinoin destabilized vascular networks but failed to target vasculogenic mimicry and augmented populations of CSLCs expressing high levels of SOX2. Our results suggest that CSLCs can transdifferentiate into drug resistant CD31+-TECs, and reveal the presence of an intermediate state STEC (stem tumor-derived endothelial cell) expressing both SOX2 and CD31. CONCLUSION Our results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.
Collapse
|
42
|
Nakayama M, Goto S, Satomi K, Yuhara M, Goseki Y, Uchiyama T, Aizawa Y. P1703Prevalence and mechanism of J waves in the middle- and high-aged subject: with a special reference to patients after percutaneous coronary intervention. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Nihira H, Nakagawa K, Izawa K, Kawai T, Yasumi T, Nishikomori R, Nambu M, Miyagawa-Hayashino A, Nomura T, Kabashima K, Ito M, Iwaki-Egawa S, Sasahara Y, Nakayama M, Heike T. Fever of unknown origin with rashes in early infancy is indicative of adenosine deaminase type 2 deficiency. Scand J Rheumatol 2017; 47:170-172. [DOI: 10.1080/03009742.2017.1324912] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- H Nihira
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - K Nakagawa
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - K Izawa
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - T Kawai
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - T Yasumi
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - R Nishikomori
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - M Nambu
- Department of Pediatrics, Tenri Hospital, Tenri, Japan
| | - A Miyagawa-Hayashino
- Department of Diagnostic Pathology, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - T Nomura
- Department of Dermatology, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - K Kabashima
- Department of Dermatology, Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - M Ito
- Department of Life Sciences, Hokkaido Pharmaceutical University School of Pharmacy, Sapporo, Japan
| | - S Iwaki-Egawa
- Department of Life Sciences, Hokkaido Pharmaceutical University School of Pharmacy, Sapporo, Japan
| | - Y Sasahara
- Department of Pediatrics, Faculty of Medicine, Tohoku University, Sendai, Japan
| | - M Nakayama
- Kazusa DNA Research Institute, Kisarazu, Japan
| | - T Heike
- Department of Pediatrics, Faculty of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
44
|
Schaede U, Mahlich J, Nakayama M, Kobayashi H, Takahashi Y, Saito K, Uemura H, Tokumitsu M, Yoshizawa K. Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions. J Glob Oncol 2017; 4:1-9. [PMID: 30241183 PMCID: PMC6180796 DOI: 10.1200/jgo.2016.008045] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
This article adds the Japanese perspective to our knowledge of shared
decision-making (SDM) preferences by surveying patients with prostate cancer
(PCA) and physicians in Japan. In 2015, 103 Japanese patients with PCA were
asked about their SDM preferences by using an Internet-based 5-point-scale
questionnaire. Concurrently, 127 Japanese physicians were surveyed regarding
their perceptions of patient preferences on SDM. Drivers of preferences and
perceptions were analyzed using univariable ordinal logistic regression and
graphing the fitted response probabilities. Although 41% of both patients and
physicians expressed and expected a desire for active involvement in treatment
decisions (a higher rate than in a similar study for the United States in 2001),
almost half the Japanese patients preferred SDM, but only 33% of physicians
assumed this was their choice. That is, 29% of Japanese physicians
underestimated patients’ preference for involvement in making treatment
decisions. Patients with lower health-related quality of life (as measured by
the Functional Assessment of Cancer Therapy-Prostate [FACT-P]) expressed a
stronger preference for SDM. The study shows that the worse the medical
situation, the more patients with PCA prefer to be involved in the treatment
decision, yet physicians tend to underestimate the preferences of their
patients. Perhaps in contrast to common assumptions, Japanese patients are as
interested in being involved in decision making as are patients in the United
States.
Collapse
Affiliation(s)
- Ulrike Schaede
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Jörg Mahlich
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Masahiko Nakayama
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Hisanori Kobayashi
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Yuriko Takahashi
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Katsuhiko Saito
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Hiroji Uemura
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Masayuki Tokumitsu
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| | - Kazutake Yoshizawa
- Ulrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan
| |
Collapse
|
45
|
Kondo T, Ochi M, Nakayama M, Taniguchi H, Akebi S, Kuroda K, Arita M, Sakai S, Namatame H, Taniguchi M, Maeno Y, Arita R, Shin S. Orbital-Dependent Band Narrowing Revealed in an Extremely Correlated Hund's Metal Emerging on the Topmost Layer of Sr_{2}RuO_{4}. Phys Rev Lett 2016; 117:247001. [PMID: 28009182 DOI: 10.1103/physrevlett.117.247001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2016] [Indexed: 06/06/2023]
Abstract
We use a surface-selective angle-resolved photoemission spectroscopy and unveil the electronic nature on the topmost layer of Sr_{2}RuO_{4} crystal, consisting of slightly rotated RuO_{6} octahedrons. The γ band derived from the 4d_{xy} orbital is found to be about three times narrower than that for the bulk. This strongly contrasts with a subtle variation seen in the α and β bands derived from the one-dimensional 4d_{xz/yz}. This anomaly is reproduced by the dynamical mean-field theory calculations, introducing not only the on-site Hubbard interaction but also the significant Hund's coupling. We detect a coherence-to-incoherence crossover theoretically predicted for Hund's metals, which has been recognized only recently. The crossover temperature in the surface is about half that of the bulk, indicating that the naturally generated monolayer of reconstructed Sr_{2}RuO_{4} is extremely correlated and well isolated from the underlying crystal.
Collapse
Affiliation(s)
- Takeshi Kondo
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - M Ochi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - M Nakayama
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - H Taniguchi
- Department of Materials Science and Engineering, Iwate University, Morioka 020-8551, Japan
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - S Akebi
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - K Kuroda
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - M Arita
- Hiroshima Synchrotron Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - S Sakai
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - H Namatame
- Hiroshima Synchrotron Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
| | - M Taniguchi
- Hiroshima Synchrotron Center, Hiroshima University, Higashi-Hiroshima 739-0046, Japan
- Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - Y Maeno
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - R Arita
- RIKEN Center for Emergent Matter Science (CEMS), Wako, Saitama 351-0198, Japan
| | - S Shin
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| |
Collapse
|
46
|
Nakayama M, Kobayashi H, Takahara T, Nishimura Y, Fukushima K, Yoshizawa K. A comparison of overall survival with 40 and 50 mg/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data. Gynecol Oncol 2016; 143:246-251. [DOI: 10.1016/j.ygyno.2016.08.331] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 08/23/2016] [Accepted: 08/24/2016] [Indexed: 12/21/2022]
|
47
|
Iwai T, Yamada T, Takahashi G, Matsumoto S, Koizumi M, Shinji S, Matsuda A, Yokoyama Y, Hara K, Takeda K, Nakayama M, Kitano S, Ohta K, Uchida E. Circulating cell-free DNA can predict relapse after resection of metastatic liver tumors from colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Tanaka H, Furuya T, Kumazaki Y, Nakayama M, Nishimura H, Ruschin M, Pinnaduwage D, Phua J, Thibault I, St-Hilaire J, Ma L, Sahgal A, Shikama N, Karasawa K. An International Multi-Institutional Planning Study Reducing Interinstitutional Variations for Spine Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
49
|
Shiono S, Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, Yoshiya K, Higashiyama M, Kameyama K, Adachi H, Shiomi K, Kanzaki M, Yoshimura M, Matsuura M, Hata Y, Chen F, Yoshida K, Sasaki H, Horio H, Takenoyama M, Yamashita M, Hashimoto T, Fujita A, Okumura M, Funai K, Asano H, Suzuki M, Shiraishi Y, Nakayama M, Yamada S, Hoshi E, Yamazaki N, Matsuo T, Miyazawa H, Sato Y, Takao M, Nakamura H, Nakayama H, Shimizu K, Watanabe T, Suzuki H, Kataoka M, Tsunezuka Y, Akamine S, Kadokura M, Hyodo I, Nakata M, Mori K, Kondo H. O-089OUTCOMES OF SEGMENTECTOMY AND WEDGE RESECTION FOR PULMONARY COLORECTAL CANCER METASTASES. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Nakayama M, Kondo T, Tian Z, Ishikawa JJ, Halim M, Bareille C, Malaeb W, Kuroda K, Tomita T, Ideta S, Tanaka K, Matsunami M, Kimura S, Inami N, Ono K, Kumigashira H, Balents L, Nakatsuji S, Shin S. Slater to Mott Crossover in the Metal to Insulator Transition of Nd_{2}Ir_{2}O_{7}. Phys Rev Lett 2016; 117:056403. [PMID: 27517783 DOI: 10.1103/physrevlett.117.056403] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Indexed: 06/06/2023]
Abstract
We present an angle-resolved photoemission study of the electronic structure of the three-dimensional pyrochlore iridate Nd_{2}Ir_{2}O_{7} through its magnetic metal-insulator transition. Our data reveal that metallic Nd_{2}Ir_{2}O_{7} has a quadratic band, touching the Fermi level at the Γ point, similar to that of Pr_{2}Ir_{2}O_{7}. The Fermi node state is, therefore, a common feature of the metallic phase of the pyrochlore iridates. Upon cooling below the transition temperature, this compound exhibits a gap opening with an energy shift of quasiparticle peaks like a band gap insulator. The quasiparticle peaks are strongly suppressed, however, with further decrease of temperature, and eventually vanish at the lowest temperature, leaving a nondispersive flat band lacking long-lived electrons. We thereby identify a remarkable crossover from Slater to Mott insulators with decreasing temperature. These observations explain the puzzling absence of Weyl points in this material, despite its proximity to the zero temperature metal-insulator transition.
Collapse
Affiliation(s)
- M Nakayama
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - Takeshi Kondo
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - Z Tian
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - J J Ishikawa
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - M Halim
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - C Bareille
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - W Malaeb
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
- Physics Department, Faculty of Science, Beirut Arab University, Beirut 11-5020, Lebanon
| | - K Kuroda
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - T Tomita
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| | - S Ideta
- UVSOR Facility, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - K Tanaka
- UVSOR Facility, Institute for Molecular Science, Okazaki 444-8585, Japan
| | - M Matsunami
- Toyota Technological Institute, Nagoya 468-8511, Japan
| | - S Kimura
- Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka 565-0871, Japan
| | - N Inami
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Ono
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Kumigashira
- Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - L Balents
- Kavli Institute for Theoretical Physics, Santa Barbara, California 93106, USA
| | - S Nakatsuji
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
- CREST, Japan Science and Technology Agency (JST), 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan
| | - S Shin
- ISSP, University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| |
Collapse
|